Design, synthesis and antitumor activity of aromatic urea-quinazolines

Future Med Chem. 2019 Nov;11(21):2821-2830. doi: 10.4155/fmc-2019-0220. Epub 2019 Sep 12.

Abstract

Background: Gefitinib and sorafenib have been proved effective for the treatment of cancers in clinical practice for years. Materials & methods: We intended to integrate the structural features of gefitinib and sorafenib and construct structurally unique 7-aromatic ureido-4-anilinoquinazolines. Results: Most of the targets exhibited promising antitumor activities. 8u showed excellent antitumor activities against the three tested cell lines (IC50, 0.81-2.49 μM). The enzymatic, apoptosis assay of 8u were also performed to study their preliminary action of mechanism. Conclusion: 8u deserve further research as antitumor agents.

Keywords: EGFR; TKI; VEGFR-2; antitumor; aromatic urea-quinazoline.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Drug Design*
  • Drug Screening Assays, Antitumor
  • Humans
  • Quinazolines / chemical synthesis
  • Quinazolines / chemistry*
  • Quinazolines / pharmacology*
  • Urea / chemistry*

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Urea